The DOI matches its Crossref record; 218 of the 218 references it cites were found in a registry or an index.
The secret ally: immunostimulation by anticancer drugs
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.150 · Cited by 3,399
Self-citationCalreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Self-citationApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Self-citationTargeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Galluzzi, L., Vitale, I., Abrams, J. M., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., Dawson, T. M., Dawson, V. L., El-Deiry, W. S., Fulda, S., et al. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2011.96 · Cited by 2,421
Self-citationTumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
Self-citationA minute chromosome in human chronic granulocytic leukemia
Nowell̀, P. C. (1960) · Science · Cited by 2,269
Chemotherapy and the war on cancer
Chabner, B. A., & Roberts, T. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1529 · Cited by 2,154
Help for cytotoxic-T-cell responses is mediated by CD40 signalling
Bennett, S. R. M., Carbone, F. R., Karamalis, F., Flavell, R. A., Miller, J. F. A. P., & Heath, W. R. (1998) · Nature · doi:10.1038/30996 · Cited by 2,092
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Self-citationStromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,808
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
Mathew, R., Karantza-Wadsworth, V., & White, E. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2254 · Cited by 1,798
Friends or foes — bipolar effects of the tumour stroma in cancer
Mueller, M. M., & Fusenig, N. E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1477 · Cited by 1,765
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Self-citationCD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,632
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Self-citationFourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Complement regulators and inhibitory proteins
Zipfel, P. F., & Skerka, C. (2009) · Nature Reviews Immunology · doi:10.1038/nri2620 · Cited by 1,264
Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245
Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, E., Le Cesne, A., Zitvogel, L., & Chauffert, B. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,241
Self-citationDiaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,215
Immunogenic and tolerogenic cell death
Green, D. R., Ferguson, T., Zitvogel, L., & Kroemer, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2545 · Cited by 1,176
Self-citationImmunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
Self-citationSuppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134
Pannexin 1 channels mediate ‘find-me’ signal release and membrane permeability during apoptosis
Chekeni, F. B., Elliott, M. R., Sandilos, J. K., Walk, S. F., Kinchen, J. M., Lazarowski, E. R., Armstrong, A. J., Penuela, S., Laird, D. W., Salvesen, G. S., et al. (2010) · Nature · doi:10.1038/nature09413 · Cited by 1,120
Stattic: a small-molecule inhibitor of STAT3 activation and dimerization
Schust, J., Sperl, B., Hollis, A., Mayer, T. U., & Berg, T. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.09.018 · Cited by 1,105
(2011) · Hepatogastroenterology · doi:10.5754/hge11427 · Cited by 953
Fu, J., Xu, D., Liu, Z., Shi, M., Zhao, P., Fu, B., Zhang, Z., Yang, H., Zhang, H., Zhou, C., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.102 · Cited by 897
Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A., Rayman, P. A., Wood, L., Garcia, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1332 · Cited by 862
Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death
Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A., Chapman, D. C., Durchschlag, M., Joza, N., Pierron, G., van Endert, P., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.1 · Cited by 848
Self-citationMitotic catastrophe: a mechanism for avoiding genomic instability
Vitale, I., Galluzzi, L., Castedo, M., & Kroemer, G. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3115 · Cited by 834
Self-citationBiological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
Desmedt, C., Haibe-Kains, B., Wirapati, P., Buyse, M., Larsimont, D., Bontempi, G., Delorenzi, M., Piccart, M., & Sotiriou, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4756 · Cited by 828
The Chronic Myelogenous Leukemia-Specific P210 Protein Is the Product of the bcr / abl Hybrid Gene
Ben-Neriah, Y., Daley, G. Q., Mes-Masson, A.-M., Witte, O. N., & Baltimore, D. (1986) · Science · doi:10.1126/science.3460176 · Cited by 806
IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer
Gyrd-Hansen, M., & Meier, P. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2889 · Cited by 790
De Monte, L., Reni, M., Tassi, E., Clavenna, D., Papa, I., Recalde, H., Braga, M., Di Carlo, V., Doglioni, C., & Protti, M. P. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101876 · Cited by 695
Inflammation and necrosis promote tumour growth
Vakkila, J., & Lotze, M. T. (2004) · Nature Reviews Immunology · doi:10.1038/nri1415 · Cited by 690
Shrimali, R. K., Yu, Z., Theoret, M. R., Chinnasamy, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0153 · Cited by 677
Immune parameters affecting the efficacy of chemotherapeutic regimens
Zitvogel, L., Kepp, O., & Kroemer, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.223 · Cited by 669
Self-citationApperley, J. F., Gardembas, M., Melo, J. V., Russell-Jones, R., Bain, B. J., Baxter, E. J., Chase, A., Chessells, J. M., Colombat, M., Dearden, C. E., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020150 · Cited by 630
Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Hartmann, J., Haap, M., Kopp, H.-G., & Lipp, H.-P. (2009) · Current Drug Metabolism · doi:10.2174/138920009788897975 · Cited by 630
Decoding Cell Death Signals in Inflammation and Immunity
Zitvogel, L., Kepp, O., & Kroemer, G. (2010) · Cell · doi:10.1016/j.cell.2010.02.015 · Cited by 558
Self-citationArnould, L., Gelly, M., Penault-Llorca, F., Benoit, L., Bonnetain, F., Migeon, C., Cabaret, V, Fermeaux, V, Bertheau, P., Garnier, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602930 · Cited by 545
Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis
Cronstein, B. N. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.3 · Cited by 535
Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521
Balachandran, V. P., Cavnar, M. J., Zeng, S., Bamboat, Z. M., Ocuin, L. M., Obaid, H., Sorenson, E. C., Popow, R., Ariyan, C., Rossi, F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2438 · Cited by 521
Induction of Lymphoidlike Stroma and Immune Escape by Tumors That Express the Chemokine CCL21
Shields, J. D., Kourtis, I. C., Tomei, A. A., Roberts, J. M., & Swartz, M. A. (2010) · Science · doi:10.1126/science.1185837 · Cited by 506
Xin, H., Zhang, C., Herrmann, A., Du, Y., Figlin, R., & Yu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4323 · Cited by 504
Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S., & Djeu, J. Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0733 · Cited by 500
Finke, J. H., Rini, B., Ireland, J., Rayman, P., Richmond, A., Golshayan, A., Wood, L., Elson, P., Garcia, J., Dreicer, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5212 · Cited by 492
The role of PI3K in immune cells
Koyasu, S. (2003) · Nature Immunology · doi:10.1038/ni0403-313 · Cited by 487
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., Kim, Y. H., Hoppe, R. T., Knox, S. J., Shin, L. K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9793 · Cited by 487
Cardiac side-effects of cancer chemotherapy
Monsuez, J.-J., Charniot, J.-C., Vignat, N., & Artigou, J.-Y. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.03.003 · Cited by 467
Nowak, A. K., Lake, R. A., Marzo, A. L., Scott, B., Heath, W. R., Collins, E. J., Frelinger, J. A., & Robinson, B. W. S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.4905 · Cited by 463
Ramakrishnan, R., Assudani, D., Nagaraj, S., Hunter, T., Cho, H.-I., Antonia, S., Altiok, S., Celis, E., & Gabrilovich, D. I. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40269 · Cited by 460
Petersen, R. P., Campa, M. J., Sperlazza, J., Conlon, D., Joshi, M., Harpole, D. H., & Patz, E. F. (2006) · Cancer · doi:10.1002/cncr.22282 · Cited by 433
Cancer immunotherapy – revisited
Lesterhuis, W. J., Haanen, J. B. A. G., & Punt, C. J. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3500 · Cited by 427
Three new types of viral oncogene of cellular origin specific for haematopoietic cell transformation
Roussel, M., Saule, S., Lagrou, C., Rommens, C., Beug, H., Graf, T., & Stehelin, D. (1979) · Nature · doi:10.1038/281452a0 · Cited by 423
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
Nowak, A. K., Robinson, B. W. S., & Lake, R. (2003) · PubMed · Cited by 421
Halama, N., Michel, S., Kloor, M., Zoernig, I., Benner, A., Spille, A., Pommerencke, T., von Knebel, D. M., Folprecht, G., Luber, B., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0268 · Cited by 420
Martins, I., Kepp, O., Schlemmer, F., Adjemian, S., Tailler, M., Shen, S., Michaud, M., Menger, L., Gdoura, A., Tajeddine, N., et al. (2011) · Oncogene · doi:10.1038/onc.2010.500 · Cited by 414
Self-citationDrug interactions in cancer therapy
Scripture, C. D., & Figg, W. D. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1887 · Cited by 366
Schiavoni, G., Sistigu, A., Valentini, M., Mattei, F., Sestili, P., Spadaro, F., Sanchez, M., Lorenzi, S., D'Urso, M. T., Belardelli, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2788 · Cited by 362
Liu, W. M., Fowler, D. W., Smith, P., & Dalgleish, A. G. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605465 · Cited by 356
Yuan, J., Gnjatic, S., Li, H., Powel, S., Gallardo, H. F., Ritter, E., Ku, G. Y., Jungbluth, A. A., Segal, N. H., Rasalan, T. S., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810114105 · Cited by 348
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
Delahaye, N. F., Rusakiewicz, S., Martins, I., Ménard, C., Roux, S., Lyonnet, L., Paul, P., Sarabi, M., Chaput, N., Semeraro, M., et al. (2011) · Nature Medicine · doi:10.1038/nm.2366 · Cited by 341
Self-citationLesterhuis, W. J., Punt, C. J. A., Hato, S. V., Eleveld-Trancikova, D., Jansen, B. J. H., Nierkens, S., Schreibelt, G., de Boer, A., Van Herpen, C. M. L., Kaanders, J. H., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43656 · Cited by 340
Rakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, A., Fan, A. C., Yang, Q., Braunstein, L., Crosby, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.002 · Cited by 339
Personalized medicine in oncology: the future is now
Schilsky, R. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3181 · Cited by 337
Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy
Ma, Y., Aymeric, L., Locher, C., Mattarollo, S. R., Delahaye, N. F., Pereira, P., Boucontet, L., Apetoh, L., Ghiringhelli, F., Casares, N., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100269 · Cited by 337
Self-citationPivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors
Mattarollo, S. R., Loi, S., Duret, H., Ma, Y., Zitvogel, L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0753 · Cited by 333
Self-citationLadoire, S., Martin, F., & Ghiringhelli, F. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1046-y · Cited by 331
Czernilofsky, A. P., Levinson, A. D., Varmus, H. E., Bishop, J. M., Tischer, E., & Goodman, H. M. (1980) · Nature · doi:10.1038/287198a0 · Cited by 321
Ferris, R. L., Jaffee, E. M., & Ferrone, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6360 · Cited by 320
Oncogenes and tumour suppressors take on centrosomes
Fukasawa, K. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2249 · Cited by 312
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Osada, T., Chong, G., Tansik, R., Hong, T., Spector, N., Kumar, R., Hurwitz, H. I., Dev, I., Nixon, A. B., Lyerly, H. K., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0441-x · Cited by 311
Ladoire, S., Arnould, L., Apetoh, L., Coudert, B., Martin, F., Chauffert, B., Fumoleau, P., & Ghiringhelli, F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4491 · Cited by 310
Paulson, K. G., Iyer, J. G., Tegeder, A. R., Thibodeau, R., Schelter, J., Koba, S., Schrama, D., Simonson, W. T., Lemos, B. D., Byrd, D. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.6308 · Cited by 302
Gulley, J. L., Arlen, P. M., Madan, R. A., Tsang, K.-Y., Pazdur, M. P., Skarupa, L., Jones, J. L., Poole, D. J., Higgins, J. P., Hodge, J. W., et al. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0782-8 · Cited by 297
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
Kepp, O., Galluzzi, L., Martins, I., Schlemmer, F., Adjemian, S., Michaud, M., Sukkurwala, A. Q., Menger, L., Zitvogel, L., & Kroemer, G. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9273-4 · Cited by 297
Self-citationSchade, A. E., Schieven, G. L., Townsend, R., Jankowska, A. M., Susulic, V., Zhang, R., Szpurka, H., & Maciejewski, J. P. (2008) · Blood · doi:10.1182/blood-2007-04-084814 · Cited by 296
Seggewiss, R. (2005) · Blood · doi:10.1182/blood-2004-07-2527 · Cited by 290
Hipp, M. M., Hilf, N., Walter, S., Werth, D., Brauer, K. M., Radsak, M. P., Weinschenk, T., Singh-Jasuja, H., & Brossart, P. (2008) · Blood · doi:10.1182/blood-2007-02-075945 · Cited by 288
Arlen, P. M., Gulley, J. L., Parker, C., Skarupa, L., Pazdur, M., Panicali, D., Beetham, P., Tsang, K. Y., Grosenbach, D. W., Feldman, J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2059 · Cited by 287
Chemotherapy induces ATP release from tumor cells
Martins, I., Tesniere, A., Kepp, O., Michaud, M., Schlemmer, F., Senovilla, L., Séror, C., Métivier, D., Perfettini, J.-L., Zitvogel, L., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.22.10026 · Cited by 278
Self-citationWang, W., Lau, R., Yu, D., Zhu, W., Korman, A., & Weber, J. (2009) · International Immunology · doi:10.1093/intimm/dxp072 · Cited by 277
Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma
Komohara, Y., Hasita, H., Ohnishi, K., Fujiwara, Y., Suzu, S., Eto, M., & Takeya, M. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01945.x · Cited by 264
Fujimoto, H., Sangai, T., Ishii, G., Ikehara, A., Nagashima, T., Miyazaki, M., & Ochiai, A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24378 · Cited by 263
Stam, K., Heisterkamp, N., Grosveld, G., de Klein, A., Verma, R. S., Coleman, M., Dosik, H., & Groffen, J. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132301 · Cited by 251
Wilson, N. S., Yang, B., Yang, A., Loeser, S., Marsters, S., Lawrence, D., Li, Y., Pitti, R., Totpal, K., Yee, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.012 · Cited by 248
Adams, S., O'Neill, D. W., Nonaka, D., Hardin, E., Chiriboga, L., Siu, K., Cruz, C. M., Angiulli, A., Angiulli, F., Ritter, E., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.776 · Cited by 247
Shurin, G. V., Tourkova, I. L., Kaneno, R., & Shurin, M. R. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900734 · Cited by 242
CpG Blocks Immunosuppression by Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Zoglmeier, C., Bauer, H., Nörenberg, D., Wedekind, G., Bittner, P., Sandholzer, N., Rapp, M., Anz, D., Endres, S., & Bourquin, C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2672 · Cited by 238
Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation
Pedroza-Gonzalez, A., Xu, K., Wu, T.-C., Aspord, C., Tindle, S., Marches, F., Gallegos, M., Burton, E. C., Savino, D., Hori, T., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20102131 · Cited by 237
Emens, L. A., Asquith, J. M., Leatherman, J. M., Kobrin, B. J., Petrik, S., Laiko, M., Levi, J., Daphtary, M. M., Biedrzycki, B., Wolff, A. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3494 · Cited by 236
Ding, T., Xu, J., Wang, F., Shi, M., Zhang, Y., Li, S.-P., & Zheng, L. (2009) · Human Pathology · doi:10.1016/j.humpath.2008.08.011 · Cited by 232
Garnett, C. T., Schlom, J., & Hodge, J. W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4025 · Cited by 232
Ge, Y., Domschke, C., Stoiber, N., Schott, S., Heil, J., Rom, J., Blumenstein, M., Thum, J., Sohn, C., Schneeweiss, A., et al. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1106-3 · Cited by 228
Hirschhorn-Cymerman, D., Rizzuto, G. A., Merghoub, T., Cohen, A. D., Avogadri, F., Lesokhin, A. M., Weinberg, A. D., Wolchok, J. D., & Houghton, A. N. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082205 · Cited by 227
In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
Ladoire, S., Mignot, G., Dabakuyo, S., Arnould, L., Apetoh, L., Rébé, C., Coudert, B., Martin, F., Bizollon, M. H., Vanoli, A., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2866 · Cited by 226
Dowell, J., Minna, J. D., & Kirkpatrick, P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1612 · Cited by 219
Adotevi, O., Pere, H., Ravel, P., Haicheur, N., Badoual, C., Merillon, N., Medioni, J., Peyrard, S., Roncelin, S., Verkarre, V., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181f4c208 · Cited by 213
Correale, P., Rotundo, M. S., Del Vecchio, M. T., Remondo, C., Migali, C., Ginanneschi, C., Tsang, K. Y., Licchetta, A., Mannucci, S., Loiacono, L., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181d32f01 · Cited by 210
Ménard, C., Blay, J.-Y., Borg, C., Michiels, S., Ghiringhelli, F., Robert, C., Nonn, C., Chaput, N., Taïeb, J., Delahaye, N. F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3807 · Cited by 202
Self-citationChemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines
Taieb, J., Chaput, N., Schartz, N., Roux, S., Novault, S., Ménard, C., Ghiringhelli, F., Terme, M., Carpentier, A. F., Darrasse-Jèse, G., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.5.2722 · Cited by 200
Self-citationBonertz, A., Weitz, J., Pietsch, D.-H. K., Rahbari, N. N., Schlude, C., Ge, Y., Juenger, S., Vlodavsky, I., Khazaie, K., Jaeger, D., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39608 · Cited by 200
Nonomura, N., Takayama, H., Nakayama, M., Nakai, Y., Kawashima, A., Mukai, M., Nagahara, A., Aozasa, K., & Tsujimura, A. (2011) · BJU International · doi:10.1111/j.1464-410x.2010.09804.x · Cited by 197
Kamper, P., Bendix, K., Hamilton-Dutoit, S., Honore, B., Nyengaard, J. R., & d'Amore, F. (2011) · Haematologica · doi:10.3324/haematol.2010.031542 · Cited by 196
Shen, Z., Zhou, S., Wang, Y., Li, R.-L., Zhong, C., Liang, C., & Sun, Y. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0816-9 · Cited by 195
Myeloid-Derived Suppressor Cell Inhibition of the IFN Response in Tumor-Bearing Mice
Mundy-Bosse, B. L., Lesinski, G. B., Jaime-Ramirez, A. C., Benninger, K., Khan, M., Kuppusamy, P., Guenterberg, K., Kondadasula, S. V., Chaudhury, A. R., La Perle, K. M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2670 · Cited by 189
Multifactorial Approach to Predicting Resistance to Anthracyclines
Desmedt, C., Di Leo, A., de Azambuja, E., Larsimont, D., Haibe-Kains, B., Selleslags, J., Delaloge, S., Duhem, C., Kains, J.-P., Carly, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.2231 · Cited by 181
Eerola, A., Soini, Y., & Pääkkö, P. K. (2000) · PubMed · Cited by 177
The role of tumor stroma in the interaction between tumor and immune system
Blankenstein, T. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.01.008 · Cited by 176
Staaf, J., Ringnér, M., Vallon-Christersson, J., Jönsson, G., Bendahl, P.-O., Holm, K., Arason, A., Gunnarsson, H., Hegardt, C., Agnarsson, B. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8775 · Cited by 175
Prognostic Significance of Macrophage Infiltration in Leiomyosarcomas
Lee, C.-H., Espinosa, I., Vrijaldenhoven, S., Subramanian, S., Montgomery, K. D., Zhu, S., Marinelli, R. J., Peterse, J. L., Poulin, N., Nielsen, T. O., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1712 · Cited by 172
Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients
Viaud, S., Flament, C., Zoubir, M., Pautier, P., LeCesne, A., Ribrag, V., Soria, J.-C., Marty, V., Vielh, P., Robert, C., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1259 · Cited by 170
Self-citation和田, 純., Suzuki, H. Y., Fuchino, R., Yamasaki, A., Nagai, S., Yanai, K., Koga, K., Nakamura, M., Tanaka, M., Morisaki, T., et al. (2009) · PubMed · Cited by 169
Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes
Pollack, B. P., Sapkota, B., & Cartee, T. V. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3283 · Cited by 169
Touzé, A., Le Bidre, E., Laude, H., Fleury, M. J. J., Cazal, R., Arnold, F., Carlotti, A., Maubec, E., Aubin, F., Avril, M.-F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1704 · Cited by 166
Circulating anti‐MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer
Hamanaka, Y., Suehiro, Y., Fukui, M., Shikichi, K., Imai, K., & Hinoda, Y. (2003) · International Journal of Cancer · doi:10.1002/ijc.10801 · Cited by 165
Larmonier, N., Janikashvili, N., LaCasse, C. J., Larmonier, C. B., Cantrell, J., Situ, E., Lundeen, T., Bonnotte, B., & Katsanis, E. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6955 · Cited by 160
Moy, B., Kirkpatrick, P. N., Kar, S., & Goss, P. E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2332 · Cited by 157
Kaneno, R., Shurin, G. V., Tourkova, I. L., & Shurin, M. R. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-58 · Cited by 156
Zappasodi, R., Pupa, S. M., Ghedini, G. C., Bongarzone, I., Magni, M., Cabras, A. D., Colombo, M. P., Carlo‐Stella, C., Gianni, A. M., & Nicola, M. D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1825 · Cited by 150
Schietinger, A., Philip, M., Liu, R. B., Schreiber, K., & Schreiber, H. W. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20092450 · Cited by 150
Weiner, H. L., & Cohen, J. A. (2002) · Multiple Sclerosis Journal · doi:10.1191/1352458502ms790oa · Cited by 148
IAP inhibitors enhance co-stimulation to promote tumor immunity
Dougan, M. L., Dougan, S. K., Slisz, J. K., Firestone, B., Vanneman, M. W., Draganov, D., Goyal, G., Li, W., Neuberg, D. S., Blumberg, R. S., et al. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20101123 · Cited by 147
Desar, I. M. E., Jacobs, J. F. M., Hulsbergen‐vandeKaa, C. A., Oyen, W. J. G., Mulders, P., van der Graaf, W. T. A., Adema, G. J., van Herpen, C. M. L., & de Vries, I. J. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25674 · Cited by 140
Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib
Weichsel, R., Dix, C., Wooldridge, L., Clement, M., Fenton-May, A. E., Sewell, A. K., Zezula, J., Greiner, E., Emma Gostick, D., Price, D. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4393 · Cited by 137
Gefitinib induces myeloid differentiation of acute myeloid leukemia
Stegmaier, K., Corsello, S. M., Ross, K. N., Wong, J. S., DeAngelo, D. J., & Golub, T. R. (2005) · Blood · doi:10.1182/blood-2005-02-0488 · Cited by 132
Ait‐Tahar, K., Damm‐Welk, C., Burkhardt, B., Zimmermann, M., Klapper, W., Reiter, A., Pulford, K. A. F., & Woessmann, W. (2010) · Blood · doi:10.1182/blood-2009-11-251892 · Cited by 132
How the Glucocorticoids Suppress Immunity
Marx, J. L. (1995) · Science · doi:10.1126/science.270.5234.232 · Cited by 130
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation
Nencioni, A., von Schwarzenberg, K., Brauer, K. M., Schmidt, S. M., Ballestrero, A., Grünebach, F., & Brossart, P. (2006) · Blood · doi:10.1182/blood-2005-08-3494 · Cited by 128
The immunogenicity of tumor cell death
Kepp, O., Tesnière, A., Zitvogel, L., & Kroemer, G. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32831bc375 · Cited by 125
Self-citationZhang, B. C., Gao, J., Wang, J., Rao, Z. G., Wang, B. C., & Gao, J. F. (2010) · Medical Oncology · doi:10.1007/s12032-010-9638-5 · Cited by 125
Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study
Boehrer, S., Adès, L., Braun, T., Galluzzi, L., Grosjean, J., Fabre, C., Roux, G. L., Gardin, C., Martin, A., de Botton, S., et al. (2007) · Blood · doi:10.1182/blood-2007-07-100362 · Cited by 119
Self-citationProteasome inhibition suppresses essential immune functions of human CD4+ T cells
Berges, C., Haberstock, H., Fuchs, D., Miltz, M., Sadeghi, M., Opelz, G., Daniel, V., & Naujokat, C. (2008) · Immunology · doi:10.1111/j.1365-2567.2007.02761.x · Cited by 118
Büschenfelde, C. M. Z., Hermann, C., Schmidt, B., Peschel, C., & Bernhard, H. (2002) · PubMed · Cited by 118
González-Aparicio, M., Alzuguren, P., Mauleón, I., Medina‐Echeverz, J., Hervás‐Stubbs, S., Mancheño, U., Berraondo, P., Crettaz, J. S., González‐Aseguinolaza, G., Prìeto, J., et al. (2010) · Gut · doi:10.1136/gut.2010.211722 · Cited by 117
Blake, S. J., Hughes, T. P., Mayrhofer, G., & Lyons, A. B. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.02.006 · Cited by 116
Sconocchia, G., Zlobec, I., Lugli, A., Calabrese, D., Iezzi, G., Karamitopoulou, E., Patsouris, E., Peros, G., Horcic, M., Tornillo, L., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25609 · Cited by 116
Qian, D. Z., Rademacher, B. L. S., Pittsenbarger, J., Huang, C., Myrthue, A., Higano, C. S., Garzotto, M. G., Nelson, P. S., & Beer, T. M. (2009) · The Prostate · doi:10.1002/pros.21077 · Cited by 114
Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
Wang, Y., Wang, X.-Y., Subjeck, J. R., Shrikant, P., & Kim, H. L. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.15 · Cited by 114
Oncosuppressive Functions of Autophagy
Morselli, E., Galluzzi, L., Kepp, O., Mariño, G., Michaud, M., Vitale, I., Maiuri, M. C., & Kroemer, G. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3478 · Cited by 112
Self-citationKyte, J. A., Gaudernack, G., Dueland, S., Trachsel, S., Julsrud, L., & Aamdal, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0184 · Cited by 111
Distel, L. V., Fickenscher, R., Dietel, K., Hung, A., Iro, H., Zenk, J., Nkenke, E., Büttner, M., Niedobitek, G., & Grabenbauer, G. G. (2009) · Oral Oncology · doi:10.1016/j.oraloncology.2009.05.640 · Cited by 110
Medina‐Echeverz, J., Fioravanti, J., Zabala, M., Ardaiz, N., Prìeto, J., & Berraondo, P. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001483 · Cited by 106
Chemotherapy enhances vaccine‐induced antitumor immunity in melanoma patients
Nisticò, P., Capone, I., Palermo, B., Bello, D. D., Ferraresi, V., Moschella, F., Aricò, E., Valentini, M., Bracci, L., Cognetti, F., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23886 · Cited by 105
Purcell, W. T., & Ettinger, D. S. (2003) · Current Oncology Reports · doi:10.1007/s11912-003-0098-3 · Cited by 104
Carrington, E. M., Vikstrom, I. B., Light, A., Sutherland, R. M., Londrigan, S. L., Mason, K. D., Huang, D. C. S., Lew, A. M., & Tarlinton, D. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005256107 · Cited by 104
Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab
Pander, J., Heusinkveld, M., van der Straaten, T., Jordanova, E. S., Baak-Pablo, R., Gelderblom, H., Morreau, H., van der Burg, S. H., Guchelaar, H.-J., & van Hall, T. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0239 · Cited by 101
The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to Viral Infection
Basler, M., Lauer, C., Beck, U., & Groettrup, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901596 · Cited by 101
Álvaro-Naranjo, T., Lejeune, M., Salvadó-Usach, T., Bosch, R., Reverter‐Branchat, G., Jaén, J., & Pons, L. E. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500220654 · Cited by 100
Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
Manzoni, M., Rovati, B., Ronzoni, M., Loupakis, F., Mariucci, S., Ricci, V., Gattoni, E., Salvatore, L., Tinelli, C., Villa, E., et al. (2010) · Oncology · doi:10.1159/000320609 · Cited by 97
Guerriero, J. L., Ditsworth, D., Catanzaro, J. M., Sabino, G. J., Furie, M. B., Kew, R. R., Crawford, H. C., & Zong, W. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003267 · Cited by 92
Garrido, G., Rabasa, A., Sánchez, B., López, M. V., Blanco, R., López, A., Hernández, D. R., Pérez, R., & Fernández, L. E. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003477 · Cited by 91
The BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity
Salih, J., Hilpert, J., Placke, T., Grünebach, F., Steinle, A., Salih, H. R., & Krusch, M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25233 · Cited by 90
Pölcher, M., Braun, M., Friedrichs, N., Rudlowski, C., Bercht, E., Fimmers, R., Sauerwald, A., Keyver-Paik, M.-D., Kübler, K., Büttner, R., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0817-1 · Cited by 90
Development and dynamics of robust T-cell responses to CML under imatinib treatment
Chen, C. I.-U., Maecker, H. T., & Lee, P. P. (2008) · Blood · doi:10.1182/blood-2007-12-128397 · Cited by 89
Rettig, L., Seidenberg, S., Parvanova, I., Samaras, P., Knuth, A., & Pascolo, S. (2011) · International Journal of Cancer · doi:10.1002/ijc.25756 · Cited by 83
Jiang, Q., Weiss, J. M., Back, T. C., Chan, T., Ortaldo, J. R., Guichard, S. M., & Wiltrout, R. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3968 · Cited by 82
Fei, F., Yu, Y., Schmitt, A., Rojewski, M., Chen, B., Greiner, J., Götz, M., Guillaume, P., Döhner, H., Bunjes, D. W., et al. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.05.002 · Cited by 80
Thurlow, J. K., Murillo, C. P., Hunter, K. D., Buffa, F. M., Patiar, S., Betts, G. N. J., West, C., Harris, A. L., Parkinson, E. K., Harrison, P. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8724 · Cited by 78
Maréchal, R., Schutter, J. D., Nagy, N., Demetter, P., Lemmers, A., Deviere, J. M. E., Salmon, I. J., Tejpar, S., & Laethem, J. V. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-340 · Cited by 77
Chen, J., Schmitt, A., Chen, B., Rojewski, M., RuBeler, V., Fei, F., Yu, Y., Yu, X., Ringhoffer, M., von Harsdorf, S., et al. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00234.x · Cited by 77
Cimetidine: An anticancer drug?
Kubecova, M., Kološtová, K., Pintérová, D., Kacprzak, G., & Bobek, V. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.02.004 · Cited by 75
Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells
Schmudde, M., Braun, A., Pende, D., Sonnemann, J., Klier, U., Beck, J. F., Moretta, L., & Bröker, B. M. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.06.027 · Cited by 74
Davis, I. D., Chen, Q., Morris, L., Quirk, J., Stanley, M. L., Tavarnesi, M. L., Parente, P., Cavicchiolo, T., Hopkins, W., Jackson, H. M., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211299.29632.8c · Cited by 73
Chakraborty, M., Wansley, E. K., Carrasquillo, J. A., Yu, S. G., Paik, C. H., Camphausen, K. A., Becker, M. D., Goeckeler, W. F., Schlom, J., & Hodge, J. W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0335 · Cited by 73
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
Kline, J. P., & Gajewski, T. F. (2010) · PubMed · Cited by 71
Palermo, B., Bello, D. D., Sottini, A., Serana, F., Ghidini, C., Gualtieri, N., Ferraresi, V., Catricalà, C., Belardelli, F., Proietti, E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1326 · Cited by 70
Cabillic, F., Toutirais, O., Lavoué, V., Pintière, C. T. D. L., Daniel, P., Rioux-Leclercq, N. C., Turlin, B., Mönkkönen, H., Mönkkönen, J., Boudjéma, K., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0887-0 · Cited by 70
VEGF Blockade Inhibits Lymphocyte Recruitment and Ameliorates Immune-Mediated Vascular Remodeling
Zhang, J., Silva, T., Yarovinsky, T. O., Manes, T. D., Tavakoli, S., Nie, L., Tellides, G., Pober, J. S., Bender, J. R., & Sadeghi, M. M. (2010) · Circulation Research · doi:10.1161/circresaha.109.210963 · Cited by 67
Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells
Fei, F., Yu, Y., Schmitt, A., Rojewski, M., Chen, B., Götz, M., Döhner, H., Bunjes, D. W., & Schmitt, M. W. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07433.x · Cited by 66
Lesterhuis, W. J., de Vries, I. J. M., Aarntzen, E., de Boer, A. J., Scharenborg, N. M., van de Rakt, M. W. M. M., van Spronsen, D.-J., Preijers, F. W. M. B., Figdor, C. G., Adema, G. J., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605935 · Cited by 64
Luo, Q., Gu, Y., Zheng, W., Wu, X., Gong, F., Gu, L., Sun, Y., & Xu, Q. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2010.12.011 · Cited by 60
Fraser, C. K., Blake, S. J., Diener, K. R., Lyons, A. B., Brown, M. P., Hughes, T. P., & Hayball, J. D. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.09.013 · Cited by 59
DeMichele, A. M., Gray, R. J., Horn, M., Chen, J., Aplenc, R., Vaughan, W. P., & Tallman, M. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2989 · Cited by 58
Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy
Ma, Y., Aymeric, L., Locher, C., Mattarollo, S. R., Delahaye, N. F., Pereira, P., Boucontet, L., Apétoh, L., Ghiringhelli, F., Casares, N., et al. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.201002692084c · Cited by 58
Self-citationAlbertus, D. L., Seder, C. W., Chen, G., Wang, X., Hartojo, W., Lin, L., Silvers, A. L., Thomas, D. G., Giordano, T. J., Chang, A. C., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318189f5ec · Cited by 57
Blanco, B., Pérez‐Simón, J. A., Sánchez-Abarca, L. I., Caballero‐Velázquez, T., Gutierrez-Cosío, S., Hernández‐Campo, P. M., Díez‐Campelo, M., Herrero-Sánchez, C., Rodríguez‐Serrano, C., Santamaría, C., et al. (2009) · Haematologica · doi:10.3324/haematol.2008.005017 · Cited by 57
Yang, X. (2007) · Frontiers in bioscience · doi:10.2741/2775 · Cited by 56
Induction of TNF-?, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells
Niiya, M., Niiya, K., Kiguchi, T., Shibakura, M., Asaumi, N., Shinagawa, K., Ishimaru, F., Kiura, K., Ikeda, K., Ueoka, H., et al. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0665-1 · Cited by 54
Gao, H., Lee, B.-N., Talpaz, M., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403933 · Cited by 53
Lynch, T. J., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Siegel, J., Cuillerot, J.-M., & Reck, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.7531 · Cited by 52
Molecular mechanisms of the antitumor effects of anti-CD20 antibodies
Winiarska, M., Głodkowska‐Mrówka, E., Bil, J., & Gołąb, J. (2010) · Frontiers in bioscience · doi:10.2741/3688 · Cited by 51
Cited by
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Self-citationImmunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Self-citationThe tumor microenvironment at a glance
Balkwill, F. R., Capasso, M., & Hagemann, T. (2012) · Journal of Cell Science · doi:10.1242/jcs.116392 · Cited by 1,857
Metadata
- Authors
- Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-02-03
- Volume
- 11
- Issue
- 3
- Pages
- 215-233
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2059409197
- Cited by
- 670
- References
- 218
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.